STAT Plus: Thousands of sickle cell and hemophilia patients are waiting for gene therapies. Can manufacturers keep up?

By EMILY MULLIN

ANNIE CAVANAGH/WELLCOME COLLECTION

Gene therapy companies are facing a crucial question: Can they make enough of the viral vectors that ferry repair genes into cells?

READ MORE